<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomed Biotechnol</journal-id><journal-id journal-id-type="pmc">jbb</journal-id><journal-id journal-id-type="publisher-id">Journal of Biomedicine and Biotechnology</journal-id><journal-id journal-id-type="publisher-id">JBB</journal-id><journal-title>Journal of Biomedicine and Biotechnology</journal-title><issn pub-type="ppub">1110-7243</issn><issn pub-type="epub">1110-7251</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15577189</article-id><article-id pub-id-type="pmc">1082891</article-id><article-id pub-id-type="doi">10.1155/S1110724304403088</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of Grape Seed Extract and Quercetin on Cardiovascular
and Endothelial Parameters in High-Risk Subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Clifton</surname><given-names>Peter M.</given-names></name><xref ref-type="aff" rid="a1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="a1">CSIRO Health Sciences and Nutrition, CSIRO, PO Box 10041, Adelaide BC, SA 5000, Australia</aff><author-notes><corresp id="cor1">*Peter M. Clifton: <email>peter.clifton@csiro.au</email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>12</month><year>2004</year></pub-date><volume>2004</volume><issue>5</issue><fpage>272</fpage><lpage>278</lpage><history><date date-type="received"><day>3</day><month>3</month><year>2004</year></date><date date-type="rev-recd"><day>18</day><month>5</month><year>2004</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2004</year></date></history><copyright-statement>Hindawi Publishing Corporation</copyright-statement><copyright-year>2004</copyright-year><abstract><p>Grape seed extract (GSE) has in vitro antioxidant activity but whether or not
it works in vivo is not clear. In a fully randomised, crossover
trial with 4-week treatment periods on 36 men and women
with above-average vascular risk,  we aimed to demonstrate that
2&#x02009;g/day of GSE  (1&#x02009;g of polyphenols) alone,
or with 1&#x02009;g/day of added quercetin in yoghurt, favourably alters
vascular function, endothelial function, and degree of oxidative damage
in comparison to a control yoghurt. GSE alone improved flow-mediated
dilatation determined ultrasonically by an absolute 1.1% compared
with control. There was no effect of the combination of GSE with
quercetin. No other blood or urine measure was altered. Thus
sufficient polyphenols from GSE appear to be absorbed to influence
endothelial nitric oxide production, and GSE has the potential to
favourably influence vascular function.</p></abstract></article-meta></front><body><sec sec-type="BACKGROUND"><title>BACKGROUND</title><p>Wine polyphenols have been postulated to have many favourable
effects [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, 
<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>] 
but most of this data has been obtained
in vitro [<xref ref-type="bibr" rid="B5">5</xref>,
<xref ref-type="bibr" rid="B6">6</xref>]. Grape seed extracts (GSEs) contain a high concentration
of many of the polyphenols in grape skins, in particular, the
proanthocyanidins, which are also found in red wine. Green tea also
contains polyphenols, in particular, the catechins, which are believed
to mediate many of the cancer chemopreventive effects [<xref ref-type="bibr" rid="B7">7</xref>]. Green
tea has been epidemiologically associated with protection from both
cancer and heart disease [<xref ref-type="bibr" rid="B8">8</xref>]. Although there is abundant in
vitro evidence that polyphenols have antioxidant and anticancer effects,
there is a dearth of animal and human experiments [<xref ref-type="bibr" rid="B9">9</xref>]. CSIRO
data (unpublished) indicates that GSEs inhibit low-density lipoprotein (LDL) oxidation and reduce aortic ring
constriction in vitro. Extract  of oligomeric
proanthocyanidins from other sources such as Pycnogenol from pine
bark enhances nitric oxide (NO) production from vascular endothelium
in vitro [<xref ref-type="bibr" rid="B10">10</xref>]. Grape seed proanthocyanidin extract (GSPE,
0.1% level) has been shown to reduce atherosclerosis in
cholesterol-fed rabbits by 30%&#x02013;50% probably by inhibiting LDL
oxidation as lipid levels were not altered while malondialdehyde
levels in the aorta (an index of lipid oxidation) were reduced by
25% [<xref ref-type="bibr" rid="B11">11</xref>]. 
Plasma proanthocyanidins were not detectable,
suggesting that absorption is very low. Rats given a dose as a
single bolus do have low (0.5&#x02009;<italic>&#x003bc;</italic>M) but detectable
levels. The dose of GSPE was equivalent to a dose of
3.5&#x02009;g for a 70&#x02009;kg
human [<xref ref-type="bibr" rid="B12">12</xref>]. Most over-the-counter forms of
GPSE are in doses of 50&#x02013;100&#x02009;mg with a recommendation to take
1&#x02009;capsule/day. This material has been available for many years
and is regarded as safe and nontoxic.</p><p>Quercetin, a flavanoid prominent in onions and apples, has been
epidemiologically associated with protection from coronary artery
disease and cancer [<xref ref-type="bibr" rid="B13">13</xref>, 
<xref ref-type="bibr" rid="B14">14</xref>] and is now available over the
counter in 300&#x02013;500&#x02009;mg dose forms, with daily doses of up to
1500&#x02009;mg. No clinical trials in the cardiovascular area have been
performed with quercetin although it has been shown to inhibit
monocyte adhesion to endothelial cells [<xref ref-type="bibr" rid="B15">15</xref>]. This is believed to
be the first step in the process of atherosclerosis. One trial using
4&#x02009;g/day has shown no effects on lipids, blood pressure, or platelet
activation in normal volunteers [<xref ref-type="bibr" rid="B16">16</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Cardiovascular measures produced by the HDI compliance
instrument; mean of 35 complete measures &#x000b1; SD.</p></caption><table frame="hsides" rules="groups"><tbody><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">GSE</th><th rowspan="1" colspan="1">GSE/quercetin</th><th rowspan="1" colspan="1">Control</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP (mmHg)</td><td rowspan="1" colspan="1">127 &#x000b1; 15</td><td rowspan="1" colspan="1">124 &#x000b1; 14</td><td rowspan="1" colspan="1">125 &#x000b1; 11</td><td rowspan="1" colspan="1">124 &#x000b1; 13</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BP (mmHg)</td><td rowspan="1" colspan="1">74 &#x000b1; 9</td><td rowspan="1" colspan="1">73 &#x000b1; 8</td><td rowspan="1" colspan="1">73 &#x000b1; 10</td><td rowspan="1" colspan="1">73 &#x000b1; 9</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean BP (mmHg)</td><td rowspan="1" colspan="1">94 &#x000b1; 13</td><td rowspan="1" colspan="1">91 &#x000b1; 18</td><td rowspan="1" colspan="1">94 &#x000b1; 12</td><td rowspan="1" colspan="1">91 &#x000b1; 12</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulse pressure (mmHg)</td><td rowspan="1" colspan="1">53 &#x000b1; 9</td><td rowspan="1" colspan="1">51 &#x000b1; 8</td><td rowspan="1" colspan="1">51 &#x000b1; 7</td><td rowspan="1" colspan="1">51 &#x000b1; 8</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulse rate (beats/min)</td><td rowspan="1" colspan="1">58 &#x000b1; 8</td><td rowspan="1" colspan="1">59 &#x000b1; 8</td><td rowspan="1" colspan="1">58 &#x000b1; 7</td><td rowspan="1" colspan="1">57 &#x000b1; 7</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated cardiac ejection time (ms)</td><td rowspan="1" colspan="1">335 &#x000b1; 25</td><td rowspan="1" colspan="1">337 &#x000b1; 24</td><td rowspan="1" colspan="1">336 &#x000b1; 23</td><td rowspan="1" colspan="1">333 &#x000b1; 36</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated stroke volume (mL)</td><td rowspan="1" colspan="1">93 &#x000b1; 13</td><td rowspan="1" colspan="1">92 &#x000b1; 12</td><td rowspan="1" colspan="1">93 &#x000b1; 12</td><td rowspan="1" colspan="1">94 &#x000b1; 12</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated stroke volume index (mL/m<sup>2</sup>)</td><td rowspan="1" colspan="1">47 &#x000b1; 5</td><td rowspan="1" colspan="1">47 &#x000b1; 4</td><td rowspan="1" colspan="1">47 &#x000b1; 4</td><td rowspan="1" colspan="1">47 &#x000b1; 6</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated cardiac output (L/min)</td><td rowspan="1" colspan="1">5.4 &#x000b1; 0.7</td><td rowspan="1" colspan="1">5.5 &#x000b1; 0.7</td><td rowspan="1" colspan="1">5.5 &#x000b1; 0.7</td><td rowspan="1" colspan="1">5.4 &#x000b1; 0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated cardiac output index (L/min/m<sup>2</sup>)</td><td rowspan="1" colspan="1">2.8 &#x000b1; 0.2</td><td rowspan="1" colspan="1">2.7 &#x000b1; 0.3</td><td rowspan="1" colspan="1">2.8 &#x000b1; 0.3</td><td rowspan="1" colspan="1">2.7 &#x000b1; 0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Large artery elasticity index</td><td rowspan="1" colspan="1">17.5 &#x000b1; 4.6</td><td rowspan="1" colspan="1">18.4 &#x000b1; 4.8</td><td rowspan="1" colspan="1">18.7 &#x000b1; 6.1</td><td rowspan="1" colspan="1">18.2 &#x000b1; 4.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Small artery elasticity index</td><td rowspan="1" colspan="1">7.4 &#x000b1; 3.8</td><td rowspan="1" colspan="1">7.4 &#x000b1; 3.4</td><td rowspan="1" colspan="1">7.9 &#x000b1; 3.9</td><td rowspan="1" colspan="1">7.4 &#x000b1; 3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic vascular resistance</td><td rowspan="1" colspan="1">1364 &#x000b1; 275</td><td rowspan="1" colspan="1">1345 &#x000b1; 229</td><td rowspan="1" colspan="1">1364 &#x000b1; 221</td><td rowspan="1" colspan="1">1352 &#x000b1; 209</td></tr><tr><td align="left" rowspan="1" colspan="1">Total vascular impedance</td><td rowspan="1" colspan="1">131 &#x000b1; 32</td><td rowspan="1" colspan="1">124 &#x000b1; 33</td><td rowspan="1" colspan="1">125 &#x000b1; 35</td><td rowspan="1" colspan="1">127 &#x000b1; 35</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Flow-mediated dilatation as measured by ultrasound. <italic>N</italic> = 35, mean SD. Treatments with different superscripts are different at <mml:math id="M1"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math>.</p></caption><table frame="hsides" rules="groups"><tbody><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">GSE</th><th rowspan="1" colspan="1">GSE/quercetin</th><th rowspan="1" colspan="1">Control</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td rowspan="1" colspan="1">Precompression cm<sup>&#x02212;2</sup></td><td rowspan="1" colspan="1">44.3 &#x000b1; 6.3</td><td rowspan="1" colspan="1">45.1 &#x000b1; 6.4</td><td rowspan="1" colspan="1">45.9 &#x000b1; 7.2</td><td rowspan="1" colspan="1">45.5 &#x000b1; 7.3</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td rowspan="1" colspan="1">Postcompression</td><td rowspan="1" colspan="1">46.2 &#x000b1; 5.8</td><td rowspan="1" colspan="1">47.4 &#x000b1; 6.5</td><td rowspan="1" colspan="1">47.6 &#x000b1; 7.5</td><td rowspan="1" colspan="1">47.3 &#x000b1; 7.3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">(<italic>n</italic> = 30)</td><td rowspan="1" colspan="1">(<italic>n</italic> = 35)</td><td rowspan="1" colspan="1">(<italic>n</italic> = 32)</td><td rowspan="1" colspan="1">(<italic>n</italic> = 36)</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td rowspan="1" colspan="1">Change</td><td rowspan="1" colspan="1">1.9<sup>1,2</sup> &#x000b1; 1.3</td><td rowspan="1" colspan="1">2.3<sup>1</sup> &#x000b1; 1.4</td><td rowspan="1" colspan="1">1.7<sup>2</sup> &#x000b1; 1.0</td><td rowspan="1" colspan="1">1.8<sup>2</sup> &#x000b1; 1.3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">(4.3%)</td><td rowspan="1" colspan="1">(5.1%)</td><td rowspan="1" colspan="1">(3.7%)</td><td rowspan="1" colspan="1">(4.0%)</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td rowspan="1" colspan="1">Pre-GTN</td><td rowspan="1" colspan="1">44.8 &#x000b1; 7.1</td><td rowspan="1" colspan="1">45.8 &#x000b1; 7.1</td><td rowspan="1" colspan="1">46.9 &#x000b1; 7.5</td><td rowspan="1" colspan="1">46.2 &#x000b1; 7.1</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td rowspan="1" colspan="1">Post-GTN</td><td rowspan="1" colspan="1">52.1 &#x000b1; 6.8</td><td rowspan="1" colspan="1">52.7 &#x000b1; 6.9</td><td rowspan="1" colspan="1">52.9 &#x000b1; 7.3</td><td rowspan="1" colspan="1">52.8 &#x000b1; 7.0</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">(<italic>n</italic> = 38)</td><td rowspan="1" colspan="1">(<italic>n</italic> = 30)</td><td rowspan="1" colspan="1">(<italic>n</italic> = 29)</td><td rowspan="1" colspan="1">(<italic>n</italic> = 31)</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td rowspan="1" colspan="1">Change</td><td rowspan="1" colspan="1">7.3<sup>1</sup> &#x000b1; 2.4</td><td rowspan="1" colspan="1">6.9<sup>1,2</sup> &#x000b1; 2.3</td><td rowspan="1" colspan="1">6.0<sup>2</sup> &#x000b1; 3.0</td><td rowspan="1" colspan="1">6.5<sup>1,2</sup> &#x000b1; 1.8</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">(16.3%)</td><td rowspan="1" colspan="1">(15.1%)</td><td rowspan="1" colspan="1">(12.8%)</td><td rowspan="1" colspan="1">(14.1%)</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Effect of GSE and GSE/quercetin on serum lipids mean (mmol/L) &#x000b1; SD.</p></caption><table frame="hsides" rules="groups"><tbody><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Period 1 baseline</th><th rowspan="1" colspan="1">Period 2</th><th rowspan="1" colspan="1">Period 3</th><th rowspan="1" colspan="1">Period 4</th><th rowspan="1" colspan="1">GSE</th><th rowspan="1" colspan="1">GSE/quercetin</th><th rowspan="1" colspan="1">Control</th></tr><tr><th colspan="8" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol</td><td rowspan="1" colspan="1">6.57 &#x000b1; 1.07</td><td rowspan="1" colspan="1">6.63 &#x000b1; 1.06</td><td rowspan="1" colspan="1">6.59 &#x000b1; 0.99</td><td rowspan="1" colspan="1">6.58 &#x000b1; 1.06</td><td rowspan="1" colspan="1">6.63 &#x000b1; 0.93</td><td rowspan="1" colspan="1">6.64 &#x000b1; 1.10</td><td rowspan="1" colspan="1">6.64 &#x000b1; 1.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride</td><td rowspan="1" colspan="1">1.80 &#x000b1; 0.80</td><td rowspan="1" colspan="1">1.98 &#x000b1; 1.06</td><td rowspan="1" colspan="1">1.90 &#x000b1; 0.83</td><td rowspan="1" colspan="1">1.73 &#x000b1; 0.88</td><td rowspan="1" colspan="1">1.88 &#x000b1; 0.92</td><td rowspan="1" colspan="1">1.88 &#x000b1; 0.85</td><td rowspan="1" colspan="1">1.92 &#x000b1; 1.03</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol</td><td rowspan="1" colspan="1">1.18 &#x000b1; 0.31</td><td rowspan="1" colspan="1">1.18 &#x000b1; 0.31</td><td rowspan="1" colspan="1">1.19 &#x000b1; 0.34</td><td rowspan="1" colspan="1">1.16 &#x000b1; 0.33</td><td rowspan="1" colspan="1">1.18 &#x000b1; 0.33</td><td rowspan="1" colspan="1">1.16 &#x000b1; 0.34</td><td rowspan="1" colspan="1">1.15 &#x000b1; 0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol</td><td rowspan="1" colspan="1">4.59 &#x000b1; 0.98</td><td rowspan="1" colspan="1">4.56 &#x000b1; 0.93</td><td rowspan="1" colspan="1">4.55 &#x000b1; 0.93</td><td rowspan="1" colspan="1">4.65 &#x000b1; 0.98</td><td rowspan="1" colspan="1">4.61 &#x000b1; 0.83</td><td rowspan="1" colspan="1">4.62 &#x000b1; 1.00</td><td rowspan="1" colspan="1">4.63 &#x000b1; 0.99</td></tr></tbody></table></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Effect of GSE  and GSE/quercetin on plasma CRP,
nitrate/nitrite, and adhesion molecules. <italic>N</italic> = 35, mean  SD.</p></caption><table frame="hsides" rules="groups"><tbody><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Period 1 baseline</th><th rowspan="1" colspan="1">Period 2</th><th rowspan="1" colspan="1">Period 3</th><th rowspan="1" colspan="1">Period 4</th><th rowspan="1" colspan="1">GSE</th><th rowspan="1" colspan="1">GSE/quercetin</th><th rowspan="1" colspan="1">Control</th></tr><tr><th colspan="8" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/L)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">3.63 &#x000b1; 5.01</td><td rowspan="1" colspan="1">3.48 &#x000b1; 4.19</td><td rowspan="1" colspan="1">3.69 &#x000b1; 4.17</td><td rowspan="1" colspan="1">3.40 &#x000b1; 3.53</td><td rowspan="1" colspan="1">3.63 &#x000b1; 5.10</td><td rowspan="1" colspan="1">3.73 &#x000b1; 4.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitrate (<italic>&#x003bc;</italic>mol/L)</td><td rowspan="1" colspan="1">31.1 &#x000b1; 12.7</td><td rowspan="1" colspan="1">28.0 &#x000b1; 11.0</td><td rowspan="1" colspan="1">36.9 &#x000b1; 36.7</td><td rowspan="1" colspan="1">30.0 &#x000b1; 13.2</td><td rowspan="1" colspan="1">35.6 &#x000b1; 36.7</td><td rowspan="1" colspan="1">30.5 &#x000b1; 12.4</td><td rowspan="1" colspan="1">28.4 &#x000b1; 12.7</td></tr><tr><td align="left" rowspan="1" colspan="1">ICAM1 (<italic>&#x003bc;</italic>g/mL)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">0.49 &#x000b1; 0.10</td><td rowspan="1" colspan="1">0.49 &#x000b1; 0.11</td><td rowspan="1" colspan="1">0.48 &#x000b1; 0.11</td><td rowspan="1" colspan="1">0.49 &#x000b1; 0.11</td><td rowspan="1" colspan="1">0.48 &#x000b1; 0.11</td><td rowspan="1" colspan="1">0.49 &#x000b1; 0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">VCAM1 (<italic>&#x003bc;</italic>g/mL)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">0.99 &#x000b1; 0.28</td><td rowspan="1" colspan="1">0.99 &#x000b1; 0.22</td><td rowspan="1" colspan="1">1.00 &#x000b1; 0.24</td><td rowspan="1" colspan="1">0.98 &#x000b1; 0.20</td><td rowspan="1" colspan="1">0.98 &#x000b1; 0.26</td><td rowspan="1" colspan="1">1.02 &#x000b1; 0.27</td></tr></tbody></table></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Effect of GSE and GSE/quercetin on clotting and
fibrinolytic factors. <italic>N</italic> = 35, mean SD.</p></caption><table frame="hsides" rules="groups"><tbody><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">Period 2</th><th rowspan="1" colspan="1">Period 3</th><th rowspan="1" colspan="1">Period 4</th><th rowspan="1" colspan="1">GSE</th><th rowspan="1" colspan="1">GSE/quercetin</th><th rowspan="1" colspan="1">Control</th></tr><tr><th colspan="8" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">VWF (%)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">115.58 &#x000b1; 39.12</td><td rowspan="1" colspan="1">101.66 &#x000b1; 35.82</td><td rowspan="1" colspan="1">102.37 &#x000b1; 35.55</td><td rowspan="1" colspan="1">109.11 &#x000b1; 36.06</td><td rowspan="1" colspan="1">104.50 &#x000b1; 39.58</td><td rowspan="1" colspan="1">106.00 &#x000b1; 36.40</td></tr><tr><td align="left" rowspan="1" colspan="1">PAI-1 ng/mL</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">50.47 &#x000b1; 33.51</td><td rowspan="1" colspan="1">45.22 &#x000b1; 21.41</td><td rowspan="1" colspan="1">49.27 &#x000b1; 31.72</td><td rowspan="1" colspan="1">50.47 &#x000b1; 35.77</td><td rowspan="1" colspan="1">48.58 &#x000b1; 29.24</td><td rowspan="1" colspan="1">45.90 &#x000b1; 21.41</td></tr><tr><td align="left" rowspan="1" colspan="1">PAI-1 activity</td><td rowspan="1" colspan="1">16.45 &#x000b1; 9.72</td><td rowspan="1" colspan="1">16.27 &#x000b1; 9.08</td><td rowspan="1" colspan="1">16.28 &#x000b1; 8.05</td><td rowspan="1" colspan="1">16.28 &#x000b1; 10.37</td><td rowspan="1" colspan="1">15.39 &#x000b1; 9.30</td><td rowspan="1" colspan="1">16.78 &#x000b1; 10.05</td><td rowspan="1" colspan="1">16.76 &#x000b1; 8.13</td></tr><tr><td align="left" rowspan="1" colspan="1">tPA (ng/mL)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">7.235 &#x000b1; 3.396</td><td rowspan="1" colspan="1">6.636 &#x000b1; 2.350</td><td rowspan="1" colspan="1">6.857 &#x000b1; 2.378</td><td rowspan="1" colspan="1">6.929 &#x000b1; 2.686</td><td rowspan="1" colspan="1">6.908 &#x000b1; 2.835</td><td rowspan="1" colspan="1">6.891 &#x000b1; 2.766</td></tr><tr><td align="left" rowspan="1" colspan="1">tPA activity</td><td rowspan="1" colspan="1">1.432 &#x000b1; 1.204</td><td rowspan="1" colspan="1">1.295 &#x000b1; 0.865</td><td rowspan="1" colspan="1">1.140 &#x000b1; 0.715</td><td rowspan="1" colspan="1">1.269 &#x000b1; 1.011</td><td rowspan="1" colspan="1">1.261 &#x000b1; 0.822</td><td rowspan="1" colspan="1">1.146 &#x000b1; 0.764</td><td rowspan="1" colspan="1">1.297 &#x000b1; 1.011</td></tr><tr><td align="left" rowspan="1" colspan="1">tPA/PAI-1 activity</td><td rowspan="1" colspan="1">20.37 &#x000b1; 21.63</td><td rowspan="1" colspan="1">20.91 &#x000b1; 21.15</td><td rowspan="1" colspan="1">24.46 &#x000b1; 24.06</td><td rowspan="1" colspan="1">27.11 &#x000b1; 32.45</td><td rowspan="1" colspan="1">24.12 &#x000b1; 27.75</td><td rowspan="1" colspan="1">26.05 &#x000b1; 29.90</td><td rowspan="1" colspan="1">23.04 &#x000b1; 21.3</td></tr><tr><td align="left" rowspan="1" colspan="1">tPA/PAI-1 mass</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">0.205 &#x000b1; 0.348</td><td rowspan="1" colspan="1">0.188 &#x000b1; 0.483</td><td rowspan="1" colspan="1">0.194 &#x000b1; 0.648</td><td rowspan="1" colspan="1">0.187 &#x000b1; 0.119</td><td rowspan="1" colspan="1">0.206 &#x000b1; 0.179</td><td rowspan="1" colspan="1">0.195 &#x000b1; 0.138</td></tr></tbody></table></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Effect of GSE and GSE/quercetin on urine isoprostane
(iso PGF2<italic>&#x003b1;</italic>). <italic>N</italic> = 35, mean  SD.</p></caption><table frame="hsides" rules="groups"><tbody><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Period 2</th><th rowspan="1" colspan="1">Period 3</th><th rowspan="1" colspan="1">Period 4</th><th rowspan="1" colspan="1">GSE</th><th rowspan="1" colspan="1">GSE/quercetin</th><th rowspan="1" colspan="1">Control</th></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1">Isoprostane (pg/mL)</td><td rowspan="1" colspan="1">617 &#x000b1; 348</td><td rowspan="1" colspan="1">713 &#x000b1; 507</td><td rowspan="1" colspan="1">709 &#x000b1; 578</td><td rowspan="1" colspan="1">668 &#x000b1; 407</td><td rowspan="1" colspan="1">741 &#x000b1; 644</td><td rowspan="1" colspan="1">630 &#x000b1; 362</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mmol/L)</td><td rowspan="1" colspan="1">11.59 &#x000b1; 4.92</td><td rowspan="1" colspan="1">11.37 &#x000b1; 5.51</td><td rowspan="1" colspan="1">12.72 &#x000b1; 5.46</td><td rowspan="1" colspan="1">11.59 &#x000b1; 4.92</td><td rowspan="1" colspan="1">11.69 &#x000b1; 5.23</td><td rowspan="1" colspan="1">12.72 &#x000b1; 5.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Isoprostane/creatinine pg/mg</td><td rowspan="1" colspan="1">529 &#x000b1; 392</td><td rowspan="1" colspan="1">561 &#x000b1; 327</td><td rowspan="1" colspan="1">519 &#x000b1; 328</td><td rowspan="1" colspan="1">534 &#x000b1; 362</td><td rowspan="1" colspan="1">562 &#x000b1; 416</td><td rowspan="1" colspan="1">513 &#x000b1; 254</td></tr><tr><td align="left" rowspan="1" colspan="1">Isoprostane excretion ng/d</td><td rowspan="1" colspan="1">1178 &#x000b1; 986</td><td rowspan="1" colspan="1">1243 &#x000b1; 1220</td><td rowspan="1" colspan="1">1107 &#x000b1; 743</td><td rowspan="1" colspan="1">1147 &#x000b1; 407</td><td rowspan="1" colspan="1">1270 &#x000b1; 1348</td><td rowspan="1" colspan="1">1112 &#x000b1; 694</td></tr></tbody></table></table-wrap><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Effect of GSE and GSE/quercetin on oxidised LDL levels U/L; <italic>N</italic> = 35, mean SD.</p></caption><table frame="hsides" rules="groups"><tbody><tr><th rowspan="1" colspan="1">Period 2</th><th rowspan="1" colspan="1">Period 3</th><th rowspan="1" colspan="1">Period 4</th><th rowspan="1" colspan="1">GSE</th><th rowspan="1" colspan="1">GSE/quercetin</th><th rowspan="1" colspan="1">Control</th></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><td rowspan="1" colspan="1">94973 &#x000b1; 26906</td><td rowspan="1" colspan="1">94637 &#x000b1; 24862</td><td rowspan="1" colspan="1">94359 &#x000b1; 31705</td><td rowspan="1" colspan="1">95284 &#x000b1; 24563</td><td rowspan="1" colspan="1">99142 &#x000b1; 22728</td><td rowspan="1" colspan="1">98383 &#x000b1; 22973</td></tr></tbody></table></table-wrap><p>In this study we hypothesised that 2&#x02009;g/day of GSE would
improve flow-mediated dilatation (FMD) and this might be mediated
by changes in the production of NO. We also hypothesised
that GSE and quercetin would function as antioxidants in plasma,
reduce the level of F2 isoprostane in urine, and possibly
influence the level of oxidized LDL in plasma and, secondary to
this, reduce the activation of the endothelium. This would be
assessed by changes in adhesion, clotting, and fibrinolytic molecules.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Subjects</title><p>Forty-three men and women with above-average vascular risk due to high
cholesterol, smoking, or high blood pressure were recruited by
public advertisement and screened at the Clinical Research Unit,
CSIRO Health Sciences and Nutrition, Adelaide. There were no
exclusion criteria on the basis of medication or consumption of
alcohol. Subjects were excluded if their body mass index (BMI)
was greater than 35 or if they suffered from diabetes mellitus, untreated
metabolic disorders such as thyroid or adrenal disease, liver or
kidney disease, or unstable coronary artery disease. All
subjects gave written, informed consent and the protocol was
approved by the Human Ethics Committee of CSIRO.</p><p>The trial was 12 weeks long and consisted of 3
four-week periods of a double-blind
randomised crossover with
control and active ingredients (1&#x02009;g GSE from Tarac +/&#x02212;
0.5&#x02009;g quercetin) in 240&#x02009;g of yoghurt taken twice daily.
Blood samples and vascular compliance measures were taken at
baseline and at the end of each period. The background diet was a
low-polyphenol, low-quercetin diet. This was achieved by
restricting tea and coffee to a maximum of 2 cups per day,
restricting apples to one per day, and forbidding red wine and onions
throughout the 12 weeks. Measures included FMD using ultrasound,
vascular compliance using radial pulse analysis (Hypertension
Diagnostics Inc/PulseWave CR-2000), fasting lipids, oxidized
LDL, nitrates (to assess the antioxidant effects), C reactive
protein (CRP), von Willebrand factor (VWF), tissue-type plasminogen
activator (tPA), plasminogen activator inhibitor 1 (PAI-1),
vascular cell adhesion molecule (VCAM1), and intercellular adhesion
molecule 1 (ICAM-1). Twenty-four-hour urine was collected to measure the
oxidized lipid isoprostane F<sub>2<italic>&#x003b1;</italic></sub>.</p><p>FMD was assessed in the brachial artery after blockage of blood
flow in the forearm with a blood pressure cuff at 200&#x02009;mmHg for
5 minutes. The response of the vessel 5 minutes
after administration of 100&#x02009;<italic>&#x003bc;</italic>g of glyceryl trinitrate (GTN)
sublingually was also assessed [<xref ref-type="bibr" rid="B17">17</xref>].</p></sec><sec><title>Serum lipids</title><p>Serum lipids (total cholesterol, triglyceride, HDL cholesterol) were
measured on 2 consecutive days at baseline and at the end of each
3-week intervention period. Venous blood samples (20&#x02009;mL)
were taken into plain tubes after an overnight fast of 12 hour.
Serum was separated by low-speed centrifugation at 600&#x02009;g for
10 minutes at 5<sup>&#x000b0;</sup>C (GS-6R centrifuge; Beckman,
Fullerton, Calif) and frozen at &#x02212;20<sup>&#x000b0;</sup>C. At the end of
the study, all samples from each subject were analysed within the
same analytic run. Total cholesterol and triacylglycerol were measured
on a Cobas-Bio centrifugal analyzer (Roche Diagnostica, Basel,
Switzerland) using enzymatic kits (Hofmann-La Roche Diagnostica,
Basel, Switzerland) and standard control sera. Plasma HDL-cholesterol
concentrations were measured after precipitation of apoB containing
lipoproteins by PEG 6000. The coefficients of variation
for the individual lipids were all less than 5%. The following
modification of the Friedewald equation for molar
concentrations was used to calculate LDL cholesterol in
mmol/L: total cholesterol&#x02014;(triacylglycerol/2.18)&#x02014;HDL cholesterol.</p><p>All other tests were enzyme linked immunosorbent assays (ELISAs): VWF
(Helena Laboratories, Melbourne Australia), Coaliza tPA (Chromogenix, Sweden),
Coaset tPA (Chromogenix), Coaliza PAI-1 (Chromogenix),
Coatest PAI-1 (Chromogenix), oxidised LDL: Mercodia oxidised LDL ELISA (Mercodia, Sweden), SVCAM1
(Immunokontact, Sweden), ICAM1 (Immunokontact), CRP (Alpha
Diagnostic International, Texas), 8-isoprostane (8-iso PGF2<italic>&#x003b1;</italic>)
(Cayman Chemical), nitrate/nitrite assay kit (Cayman Chemical).</p></sec><sec><title>Statistical analysis</title><p>Repeated measures analysis of variance was
calculated with type of yoghurt as the within-subject factor and
with sex and order as the between-subject factors. Where there
was a significant treatment effect detected by repeated measures,
paired Student <mml:math id="M2"><mml:mi>t</mml:mi></mml:math> tests were used to locate differences.
Bivariate correlation was conducted using
Pearson's correlation coefficient. Analyses were performed
with SPSS 10.0 for Windows (SPSS Inc, Chicago, Ill).
Significance was set at <mml:math id="M3"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math>.</p></sec></sec><sec sec-type="RESULTS AND DISCUSSION"><title>RESULTS AND DISCUSSION</title><p>Twelve women and twenty-four men completed the study and one additional
woman missed the last phase of treatment. Six subjects withdrew after
commencement and 6 withdrew prior to commencement.</p><p>The risk profile of subjects was as follows: 6 subjects had high blood pressure (5
on medication), 3 were smokers, and 31 had high cholesterol
(greater than 5&#x02009;mmol/L on finger prick). Two volunteers on atorvastatin to
lower cholesterol stopped the medication prior to beginning the trial.
The average cholesterol was 6.5&#x02009;mmol/L (range 4.68 to 8.63),
average age 58 years (range 34&#x02013;70), weight 83.1&#x02009;Kg
(63.1&#x02009;kg to 118.7&#x02009;kg), BMI 28.4 (19.8&#x02013;37.5). Mean
blood pressure was 127&#x02009;mm Hg systolic and 74&#x02009;mm Hg diastolic.</p><sec><title>Blood pressure/vascular compliance</title><p>There was a weak (<mml:math id="M4"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math>) trend to a lowering of systolic blood
pressure over the duration of the trial with a fall from 127&#x02009;mm Hg
at baseline to 124&#x02009;mm Hg at week 12. This is quite usual in
clinical trials in which blood pressure is measured. There were
no changes in any vascular parameter with
treatment (see <xref ref-type="table" rid="T1">Table 1</xref>).</p></sec><sec><title>Flow-mediated dilatation after compression release and GTN dilatation</title><p>GSE alone produced an absolute 1.1% greater
dilatation compared with control (<mml:math id="M5"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math>) but the addition of
quercetin apparently nullified this completely. GTN-induced
dilatation was not influenced by GSE but quercetin again appeared
to diminish the response compared with baseline (<mml:math id="M6"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math>), but not compared with control.</p><p>This indicates that GSE favourably influences the endothelium
enhancing NO production, release or slowing down
oxidative destruction of it, but quercetin appears to interfere
with this. It is known that quercetin inhibits LPS-induced NO
release in RAW 264.7 macrophages [<xref ref-type="bibr" rid="B18">18</xref>] and can act as a prooxidant
in other systems [<xref ref-type="bibr" rid="B19">19</xref>, 
<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>] at both low and high
levels (see <xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec><title>Serum lipids</title><p>No changes were noted but none were expected. Subjects were at
high risk of cardiovascular disease by virtue of the high average
cholesterol (see <xref ref-type="table" rid="T3">Table 3</xref>).</p></sec><sec><title>C reactive protein</title><p>CRP is an acute-phase protein produced by the liver in response
to tissue damage or inflammation and may increase 500 fold
acutely [<xref ref-type="bibr" rid="B22">22</xref>]. It is also elevated but to low levels by low-grade
inflammatory conditions such as atherosclerosis and can be used
to predict clinical events [<xref ref-type="bibr" rid="B23">23</xref>]. Statins which lower cholesterol
by inhibiting synthesis in the liver also lower CRP and the mechanism
appears to be unrelated to the degree of cholesterol lowering
[<xref ref-type="bibr" rid="B24">24</xref>]. It may be related to their antioxidant activity or a
direct anti-inflammatory activity. Thus in this study it was used to
check both for potential toxic effects and to demonstrate a
potential of GSE to act like a statin in the vessel wall. No
differences were found between periods or treatments. One person was
excluded as he had a respiratory infection requiring antibiotics
which caused a sharp rise in CRP levels (over a 100-fold rise) 
(see <xref ref-type="table" rid="T4">Table 4</xref>).</p></sec><sec><title>Nitrate/Nitrite</title><p>Plasma nitrate was measured as a surrogate index of NO
production [<xref ref-type="bibr" rid="B25">25</xref>, 
<xref ref-type="bibr" rid="B26">26</xref>]. NO is an endogenous
vasodilator produced by endothelial cells. Red wine polyphenols
enhance vasorelaxation and NO production in vitro
[<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>]. 
Ethanol itself also enhances NO production
[<xref ref-type="bibr" rid="B29">29</xref>]. No differences were found either by period
or by treatment with or without an outlier whose value rose
6-fold in the GSE period. However, dietary nitrites and nitrates
can confound this measure quite easily so the absence of change
does not mean that NO production did not rise
(see <xref ref-type="table" rid="T4">Table 4</xref>).</p></sec><sec><title>Adhesion molecules</title><p>ICAM1 and VCAM1 are molecules which bind white cells to the
endothelium and reflect the state of the health of the
endothelium, particularly in relationship to atherosclerosis
[<xref ref-type="bibr" rid="B30">30</xref>, 
<xref ref-type="bibr" rid="B31">31</xref>]. If the endothelium is damaged by oxidized lipid,
cigarette smoke, or high blood pressure, these markers increase
[<xref ref-type="bibr" rid="B32">32</xref>]. An antioxidant might be expected to lower the level of
these markers (vitamin E does in some studies [<xref ref-type="bibr" rid="B33">33</xref>]) as does a
statin which lowers plasma lipid level [<xref ref-type="bibr" rid="B34">34</xref>]. Polyphenols from
blue and red berries reduce adhesion molecules in endothelial
cells in vitro [<xref ref-type="bibr" rid="B35">35</xref>]. GSE and GSE/quercetin had no effect, nor
were there any time effects  (see <xref ref-type="table" rid="T4">Table 4</xref>).</p></sec><sec><title>Clotting and fibrinolytic factors</title><p>VWF mediates the binding of platelets to injured vessels and
protects coagulation factor VIII. It is produced in the endothelium
and is released when the endothelium is damaged by atherosclerosis,
diabetes, insulin resistance, or hypertension [<xref ref-type="bibr" rid="B36">36</xref>, 
<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>]. 
Tissue-type plasminogen activator is released from endothelial
cells to initiate the process of breaking down clots in the vessel
by activating plasminogen to plasmin which then breaks down fibrin.
Endothelial dysfunction impairs the release of active tPA [<xref ref-type="bibr" rid="B39">39</xref>]
and is associated with an enhanced release of PAI-1 [<xref ref-type="bibr" rid="B40">40</xref>]. GSE and
GSE/quercetin had no effect on VWF, tPA, or PAI-1 and there were no time effects.
In [<xref ref-type="bibr" rid="B41">41</xref>] de Maat et al  found no effect of black or green tea on any of the
markers we measured, but wine polyphenolics have been shown in
cultured human endothelial cells [<xref ref-type="bibr" rid="B42">42</xref>] to increase production of
tPA (see <xref ref-type="table" rid="T5">Table 5</xref>).</p></sec><sec><title>Urine isoprostanes</title><p>8-Isoprostane (8-iso PGF2<italic>&#x003b1;</italic>) is a stable end product formed from
arachidonic acid by free radical action and is measurable in
plasma  and urine. The level is believed to represent the degree
of oxidative stress in lipids [<xref ref-type="bibr" rid="B43">43</xref>, 
<xref ref-type="bibr" rid="B44">44</xref>].</p><p>In this experiment, we saw no changes in urinary isoprostanes either
absolute or expressed in relation to creatinine to adjust for
incomplete urinary collections (see <xref ref-type="table" rid="T6">Table 6</xref>). The values
measured in this study were in the range described for subjects
with type 2 diabetes. Vitamin E has been shown to reduce plasma
and urine isoprostanes in some studies [<xref ref-type="bibr" rid="B45">45</xref>, 
<xref ref-type="bibr" rid="B46">46</xref>] but not in
others [<xref ref-type="bibr" rid="B47">47</xref>]. Subjects with type 2 diabetes have elevated
(double) level of urinary isoprostane compared with controls
and it falls by 32% with treatment with
vitamin E [<xref ref-type="bibr" rid="B48">48</xref>]. Ide et al
[<xref ref-type="bibr" rid="B49">49</xref>] found that in  healthy young men vitamin E could reduce
urine isoprostane levels by 48%. Whole grains have been found to
lower isoprostane by 28% in one study [<xref ref-type="bibr" rid="B50">50</xref>], as did fruit and
vegetables in another study [<xref ref-type="bibr" rid="B51">51</xref>], although van den Berg found
no effects of fruit and vegetables [<xref ref-type="bibr" rid="B52">52</xref>]. Tea polyphenols did
not alter isoprostanes [<xref ref-type="bibr" rid="B53">53</xref>] while dealcoholised red wine reduced
the levels in plasma with a trend in urine [<xref ref-type="bibr" rid="B54">54</xref>].</p><p>Although the results are negative except for the FMD changes, they
are not incompatible with the current literature which is not
uniform in its results. They are also compatible with the
observed lack of change in the levels of oxidized LDL
(see <xref ref-type="table" rid="T7">Table 7</xref>) in this study. There is no published data on
measurement of oxidized LDL in plasma using this method.</p><p>There were no changes in urine chemistry, haematology, clotting,
or biochemistry with GSE or GSE/quercetin. There were some
time-related changes in urea and creatinine chloride and
bicarbonate which may have been due to warmer weather (data not shown).</p></sec></sec><sec sec-type="CONCLUSIONS"><title>CONCLUSIONS</title><p>We have demonstrated that sufficient antioxidant polyphenols from
GSE were absorbed to influence FMD but no other endothelial
functions were affected. It is known from rat and rabbit studies
that the absorption of proanthycyanidins from GSE is very
limited. In one rat study [<xref ref-type="bibr" rid="B55">55</xref>], 
after feeding 0.25&#x02009;g/kg of
GSE (equivalent to feeding over 20&#x02009;g to humans), a level of
18&#x02009;<italic>&#x003bc;</italic>g/mL of dimer was achieved after 1 hour. In the
rabbits, despite an equivalent dose spread over the day, no
proanthocyanidins were detected, even though in this model lipid
peroxidation and aortic atherosclerosis were reduced [<xref ref-type="bibr" rid="B11">11</xref>]. In
vitro studies often use levels of 10&#x02013;50&#x02009;<italic>&#x003bc;</italic>g/mL [<xref ref-type="bibr" rid="B6">6</xref>] which is 10&#x02013;20 times higher than what might be achieved in human
studies. Quercetin is known to be absorbed and 1&#x02009;g/day can produce
levels 23 times higher than control capsules. Despite this level
and its demonstrable in vitro antioxidant action, it has no effects
on platelets or lipids [<xref ref-type="bibr" rid="B56">56</xref>]. Although red wine extract inhibits
endothelin (ET-1) production, neither isolated red wine polyphenols
(quercetin, resveratrol, D-,L-catechin, D-,L-epicatechin) nor the
anthocyanins delphinidin, pelargonidin, cyanidin, peonidin, petunidin,
or malvidin affect ET-1 production [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Although there is no data yet relating impaired FMD to cardiac
events in subjects without coronary disease, those patients with
coronary disease who have very impaired FMD have more events [<xref ref-type="bibr" rid="B57">57</xref>].
Subjects with impaired FMD are more likely to have coronary disease on
angiography [<xref ref-type="bibr" rid="B58">58</xref>]. Statins improve mortality and one mechanism
may be via their improvement of FMD [<xref ref-type="bibr" rid="B59">59</xref>]. Subjects with low
acetylcholine induced forearm vasodilatation are more likely to have
acute events [<xref ref-type="bibr" rid="B60">60</xref>].</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>St Leger</surname><given-names>A.S</given-names></name><name><surname>Cochrane</surname><given-names>A.L</given-names></name><name><surname>Moore</surname><given-names>F</given-names></name></person-group><article-title>Factors associated with cardiac mortality in developed countries
with particular reference to the consumption of wine</article-title><source>Lancet</source><year>1979</year><volume>1</volume><issue>8124</issue><fpage>1017</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">86728</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Renaud</surname><given-names>S</given-names></name><name><surname>de Lorgeril</surname><given-names>M</given-names></name></person-group><article-title>Wine, alcohol, platelets, and the French
paradox for coronary heart disease</article-title><source>Lancet</source><year>1992</year><volume>339</volume><issue>8808</issue><fpage>1523</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">1351198</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aviram</surname><given-names>M</given-names></name><name><surname>Fuhrman</surname><given-names>B</given-names></name></person-group><article-title>Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and
attenuate atherogenesis</article-title><source>Atherosclerosis</source><year>1998</year><volume>137</volume><issue>suppl</issue><fpage>S45</fpage><lpage>S50</lpage><pub-id pub-id-type="pmid">9694541</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>D.K</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Ray</surname><given-names>P.S</given-names></name></person-group><article-title>Cardioprotection of red wine: role of polyphenolic antioxidants</article-title><source>Drugs Exp Clin Res</source><year>1999</year><volume>25</volume><issue>2-3</issue><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">10370873</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankel</surname><given-names>E.N</given-names></name><name><surname>Kanner</surname><given-names>J</given-names></name><name><surname>German</surname><given-names>J.B</given-names></name><name><surname>Parks</surname><given-names>E</given-names></name><name><surname>Kinsella</surname><given-names>J.E</given-names></name></person-group><article-title>Inhibition of oxidation of human low-density lipoprotein by phenolic
substances in red wine</article-title><source>Lancet</source><year>1993</year><volume>341</volume><issue>8843</issue><fpage>454</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">8094487</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corder</surname><given-names>R</given-names></name><name><surname>Douthwaite</surname><given-names>J.A</given-names></name><name><surname>Lees</surname><given-names>D.M</given-names></name><etal/></person-group><article-title>Endothelin-1 synthesis reduced by red wine</article-title><source>Nature</source><year>2001</year><volume>414</volume><issue>6866</issue><fpage>863</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">11780050</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>F.L</given-names></name><name><surname>Schwartz</surname><given-names>J</given-names></name><name><surname>Herzog</surname><given-names>C.R</given-names></name><name><surname>Yang</surname><given-names>Y.M</given-names></name></person-group><article-title>Tea and cancer prevention: studies in animals and humans</article-title><source>J Nutr</source><year>2003</year><volume>133</volume><issue>10</issue><fpage>3268S</fpage><lpage>3274S</lpage><pub-id pub-id-type="pmid">14519825</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hollman</surname><given-names>P.C</given-names></name><name><surname>Feskens</surname><given-names>E.J</given-names></name><name><surname>Katan</surname><given-names>M.B</given-names></name></person-group><article-title>Tea flavonols in cardiovascular disease and cancer epidemiology</article-title><source>Proc Soc Exp Biol Med</source><year>1999</year><volume>220</volume><issue>4</issue><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">10202388</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higdon</surname><given-names>J.V</given-names></name><name><surname>Frei</surname><given-names>B</given-names></name></person-group><article-title>Tea catechins and polyphenols: health effects, metabolism,
and antioxidant functions</article-title><source>Crit Rev Food Sci Nutr</source><year>2003</year><volume>43</volume><issue>1</issue><fpage>89</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">12587987</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzpatrick</surname><given-names>D.F</given-names></name><name><surname>Bing</surname><given-names>B</given-names></name><name><surname>Rohdewald</surname><given-names>P</given-names></name></person-group><article-title>Endothelium-dependent vascular effects of Pycnogenol</article-title><source>J Cardiovasc Pharmacol</source><year>1998</year><volume>32</volume><issue>4</issue><fpage>509</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">9781917</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamakoshi</surname><given-names>J</given-names></name><name><surname>Kataoka</surname><given-names>S</given-names></name><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Ariga</surname><given-names>T</given-names></name></person-group><article-title>Proanthocyanidin-rich extract from grape seeds attenuates
the development of aortic atherosclerosis in cholesterol-fed rabbits</article-title><source>Atherosclerosis</source><year>1999</year><volume>142</volume><issue>1</issue><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">9920515</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Osakabe</surname><given-names>N</given-names></name><name><surname>Natsume</surname><given-names>M</given-names></name><name><surname>Terao</surname><given-names>J</given-names></name></person-group><article-title>Absorption and urinary excretion of procyanidin B2
[epicatechin-(4beta-8)-epicatechin] in rats</article-title><source>Free Radic Biol Med</source><year>2002</year><volume>33</volume><issue>1</issue><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">12086692</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hertog</surname><given-names>M.G</given-names></name><name><surname>Feskens</surname><given-names>E.J</given-names></name><name><surname>Hollman</surname><given-names>P.C</given-names></name><name><surname>Katan</surname><given-names>M.B</given-names></name><name><surname>Kromhout</surname><given-names>D</given-names></name></person-group><article-title>Dietary antioxidant flavonoids and risk of coronary heart
disease: the Zutphen Elderly Study</article-title><source>Lancet</source><year>1993</year><volume>342</volume><issue>8878</issue><fpage>1007</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">8105262</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knekt</surname><given-names>P</given-names></name><name><surname>Kumpulainen</surname><given-names>J</given-names></name><name><surname>Jarvinen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Flavonoid intake and risk of chronic diseases</article-title><source>Am J Clin Nutr</source><year>2002</year><volume>76</volume><issue>3</issue><fpage>560</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">12198000</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Meydani</surname><given-names>M</given-names></name></person-group><article-title>Effect of plasma metabolites of (+)-catechin and quercetin on monocyte adhesion
to human aortic endothelial cells</article-title><source>Am J Clin Nutr</source><year>2001</year><volume>73</volume><issue>5</issue><fpage>941</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">11333849</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferry</surname><given-names>D.R</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Malkhandi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and
evidence for in vivo tyrosine kinase inhibition</article-title><source>Clin Cancer Res</source><year>1996</year><volume>2</volume><issue>4</issue><fpage>659</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">9816216</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faulx</surname><given-names>M.D</given-names></name><name><surname>Wright</surname><given-names>A.T</given-names></name><name><surname>Hoit</surname><given-names>B.D</given-names></name></person-group><article-title>Detection of endothelial dysfunction with brachial
artery ultrasound scanning</article-title><source>Am Heart J</source><year>2003</year><volume>145</volume><issue>6</issue><fpage>943</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">12796748</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wadsworth</surname><given-names>T.L</given-names></name><name><surname>Koop</surname><given-names>D.R</given-names></name></person-group><article-title>Effects of the wine polyphenolics quercetin and resveratrol on
pro-inflammatory cytokine expression in RAW 264.7 macrophages</article-title><source>Biochem Pharmacol</source><year>1999</year><volume>57</volume><issue>8</issue><fpage>941</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">10086329</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Dhawan</surname><given-names>A</given-names></name><name><surname>Yardley-Jones</surname><given-names>A</given-names></name><name><surname>Ioannides</surname><given-names>C</given-names></name><name><surname>Webb</surname><given-names>J</given-names></name></person-group><article-title>Effect of antioxidant flavonoids and a food mutagen on lymphocytes of a
thalassemia patient without chelation therapy in the Comet assay</article-title><source>Teratog Carcinog Mutagen</source><year>2001</year><volume>21</volume><issue>2</issue><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">11223893</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahu</surname><given-names>S.C</given-names></name><name><surname>Gray</surname><given-names>G.C</given-names></name></person-group><article-title>Pro-oxidant activity of flavonoids: effects on glutathione and
glutathione S-transferase in isolated rat liver nuclei</article-title><source>Cancer Lett</source><year>1996</year><volume>104</volume><issue>2</issue><fpage>193</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">8665487</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stadler</surname><given-names>R.H</given-names></name><name><surname>Markovic</surname><given-names>J</given-names></name><name><surname>Turesky</surname><given-names>R.J</given-names></name></person-group><article-title>In vitro anti- and pro-oxidative effects of natural polyphenols</article-title><source>Biol Trace Elem Res</source><year>1995</year><volume>47</volume><issue>1&#x02013;3</issue><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">7779561</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steel</surname><given-names>D.M</given-names></name><name><surname>Whitehead</surname><given-names>A.S</given-names></name></person-group><article-title>The major acute phase reactants: C-reactive protein, serum amyloid P
component and serum amyloid A protein</article-title><source>Immunol Today</source><year>1994</year><volume>15</volume><issue>2</issue><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">8155266</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Appleby</surname><given-names>P</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name></person-group><article-title>Association of fibrinogen, C-reactive protein, albumin,
or leukocyte count with coronary heart disease: meta-analyses
of prospective studies</article-title><source>JAMA</source><year>1998</year><volume>279</volume><issue>18</issue><fpage>1477</fpage><lpage>1482</lpage><pub-id pub-id-type="pmid">9600484</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balk</surname><given-names>E.M</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Goudas</surname><given-names>L.C</given-names></name><etal/></person-group><article-title>Effects of statins on nonlipid serum markers associated
with cardiovascular disease: a systematic review</article-title><source>Ann Intern Med</source><year>2003</year><volume>139</volume><issue>8</issue><fpage>670</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">14568856</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moshage</surname><given-names>H</given-names></name><name><surname>Kok</surname><given-names>B</given-names></name><name><surname>Huizenga</surname><given-names>J.R</given-names></name><name><surname>Jansen</surname><given-names>P.L</given-names></name></person-group><article-title>Nitrite and nitrate determinations in plasma: a critical evaluation</article-title><source>Clin Chem</source><year>1995</year><volume>41</volume><issue>6 pt 1</issue><fpage>892</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">7768008</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baylis</surname><given-names>C</given-names></name><name><surname>Vallance</surname><given-names>P</given-names></name></person-group><article-title>Measurement of nitrite and nitrate levels in plasma and urine&#x02014;what
does this measure tell us about the activity of the endogenous
nitric oxide system?</article-title><source>Curr Opin Nephrol Hypertens</source><year>1998</year><volume>7</volume><issue>1</issue><fpage>59</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9442364</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoclet</surname><given-names>J.C</given-names></name><name><surname>Kleschyov</surname><given-names>A</given-names></name><name><surname>Andriambeloson</surname><given-names>E</given-names></name><name><surname>Diebolt</surname><given-names>M</given-names></name><name><surname>Andriantsitohaina</surname><given-names>R</given-names></name></person-group><article-title>Endothelial NO release caused by red wine polyphenols</article-title><source>J Physiol Pharmacol</source><year>1999</year><volume>50</volume><issue>4</issue><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">10639004</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Andriambeloson</surname><given-names>E</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Andriantsitohaina</surname><given-names>R</given-names></name></person-group><article-title>Red wine polyphenols increase calcium in bovine aortic
endothelial cells: a basis to elucidate signalling pathways
leading to nitric oxide production</article-title><source>Br J Pharmacol</source><year>2002</year><volume>135</volume><issue>6</issue><fpage>1579</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">11906973</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venkov</surname><given-names>C.D</given-names></name><name><surname>Myers</surname><given-names>P.R</given-names></name><name><surname>Tanner</surname><given-names>M.A</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Vaughan</surname><given-names>D.E</given-names></name></person-group><article-title>Ethanol increases endothelial nitric oxide production
through modulation of nitric oxide synthase expression</article-title><source>Thromb Haemost</source><year>1999</year><volume>81</volume><issue>4</issue><fpage>638</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">10235453</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hope</surname><given-names>S.A</given-names></name><name><surname>Meredith</surname><given-names>I.T</given-names></name></person-group><article-title>Cellular adhesion molecules and cardiovascular disease.
Part I. Their expression and role in atherogenesis</article-title><source>Intern Med J</source><year>2003</year><volume>33</volume><issue>8</issue><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">12895171</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Basta</surname><given-names>G</given-names></name><name><surname>Lazzerini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Soluble vascular cell adhesion molecule-1 as a
biohumoral correlate of atherosclerosis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1997</year><volume>17</volume><issue>11</issue><fpage>2646</fpage><lpage>2654</lpage><pub-id pub-id-type="pmid">9409238</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazzone</surname><given-names>A</given-names></name><name><surname>Cusa</surname><given-names>C</given-names></name><name><surname>Mazzucchelli</surname><given-names>I</given-names></name><etal/></person-group><article-title>Cigarette smoking and hypertension influence nitric oxide
release and plasma levels of adhesion molecules</article-title><source>Clin Chem Lab Med</source><year>2001</year><volume>39</volume><issue>9</issue><fpage>822</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">11601680</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theriault</surname><given-names>A</given-names></name><name><surname>Chao</surname><given-names>J.T</given-names></name><name><surname>Gapor</surname><given-names>A</given-names></name></person-group><article-title>Tocotrienol is the most effective vitamin E for reducing
endothelial expression of adhesion molecules and adhesion to monocytes</article-title><source>Atherosclerosis</source><year>2002</year><volume>160</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11755919</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mueck</surname><given-names>A.O</given-names></name><name><surname>Seeger</surname><given-names>H</given-names></name><name><surname>Wallwiener</surname><given-names>D</given-names></name></person-group><article-title>Further evidence for direct vascular actions of statins:
effect on endothelial nitric oxide synthase and adhesion molecules</article-title><source>Exp Clin Endocrinol Diabetes</source><year>2001</year><volume>109</volume><issue>3</issue><fpage>181</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">11409302</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>K.A</given-names></name><name><surname>McDonald</surname><given-names>J</given-names></name><name><surname>Kalt</surname><given-names>W</given-names></name><name><surname>Joseph</surname><given-names>J.A</given-names></name></person-group><article-title>Potential role of
dietary flavonoids in reducing microvascular endothelium vulnerability
to oxidative and inflammatory insults</article-title><source>J Nutr Biochem</source><year>2002</year><volume>13</volume><issue>5</issue><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">12015158</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Preston</surname><given-names>R.A</given-names></name><name><surname>Ledford</surname><given-names>M</given-names></name><name><surname>Materson</surname><given-names>B.J</given-names></name><name><surname>Baltodano</surname><given-names>N.M</given-names></name><name><surname>Memon</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name></person-group><article-title>Effects of severe, uncontrolled hypertension on endothelial activation:
soluble vascular cell adhesion molecule-1, soluble intercellular adhesion
molecule-1 and von Willebrand factor</article-title><source>J Hypertens</source><year>2002</year><volume>20</volume><issue>5</issue><fpage>871</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">12011647</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stehouwer</surname><given-names>C.D</given-names></name><name><surname>Gall</surname><given-names>M.A</given-names></name><name><surname>Twisk</surname><given-names>J.W</given-names></name><name><surname>Knudsen</surname><given-names>E</given-names></name><name><surname>Emeis</surname><given-names>J.J</given-names></name><name><surname>Parving</surname><given-names>H.H</given-names></name></person-group><article-title>Increased urinary albumin excretion, endothelial dysfunction,
and chronic low-grade inflammation in type 2 diabetes: progressive,
interrelated, and independently associated with risk of death</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>4</issue><fpage>1157</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">11916939</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weyer</surname><given-names>C</given-names></name><name><surname>Yudkin</surname><given-names>J.S</given-names></name><name><surname>Stehouwer</surname><given-names>C.D</given-names></name><name><surname>Schalkwijk</surname><given-names>C.G</given-names></name><name><surname>Pratley</surname><given-names>R.E</given-names></name><name><surname>Tataranni</surname><given-names>P.A</given-names></name></person-group><article-title>Humoral markers of inflammation and endothelial dysfunction
in relation to adiposity and in vivo insulin action in Pima Indians</article-title><source>Atherosclerosis</source><year>2002</year><volume>161</volume><issue>1</issue><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">11882337</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newby</surname><given-names>D.E</given-names></name><name><surname>McLeod</surname><given-names>A.L</given-names></name><name><surname>Uren</surname><given-names>N.G</given-names></name><etal/></person-group><article-title>Impaired coronary tissue plasminogen activator release
is associated with coronary atherosclerosis and cigarette
smoking: direct link between endothelial dysfunction and
atherothrombosis</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>15</issue><fpage>1936</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">11306520</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huvers</surname><given-names>F.C</given-names></name><name><surname>De Leeuw</surname><given-names>P.W</given-names></name><name><surname>Houben</surname><given-names>A.J</given-names></name><etal/></person-group><article-title>Endothelium-dependent vasodilatation, plasma markers of endothelial function,
and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic
conditions</article-title><source>Diabetes</source><year>1999</year><volume>48</volume><issue>6</issue><fpage>1300</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">10342820</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Maat</surname><given-names>M.P</given-names></name><name><surname>Pijl</surname><given-names>H</given-names></name><name><surname>Kluft</surname><given-names>C</given-names></name><name><surname>Princen</surname><given-names>H.M</given-names></name></person-group><article-title>Consumption of black and green tea had no effect on inflammation,
haemostasis and endothelial markers in smoking healthy individuals</article-title><source>Eur J Clin Nutr</source><year>2000</year><volume>54</volume><issue>10</issue><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">11083483</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abou-Agag</surname><given-names>L.H</given-names></name><name><surname>Aikens</surname><given-names>M.L</given-names></name><name><surname>Tabengwa</surname><given-names>E.M</given-names></name><etal/></person-group><article-title>Polyphenolics increase t-PA and u-PA gene transcription
in cultured human endothelial cells</article-title><source>Alcohol Clin Exp Res</source><year>2001</year><volume>25</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">11236827</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>J.D</given-names></name><name><surname>Hill</surname><given-names>K.E</given-names></name><name><surname>Burk</surname><given-names>R.F</given-names></name><name><surname>Nammour</surname><given-names>T.M</given-names></name><name><surname>Badr</surname><given-names>K.F</given-names></name><name><surname>Roberts</surname><given-names>L.J</given-names></name></person-group><article-title>A series of prostaglandin F2-like compounds are produced in
vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism</article-title><source>Proc Natl Acad Sci USA</source><year>1990</year><volume>87</volume><issue>23</issue><fpage>9383</fpage><lpage>9387</lpage><pub-id pub-id-type="pmid">2123555</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pratic&#x000f2;</surname><given-names>D</given-names></name></person-group><article-title>In vivo measurement of the redox state</article-title><source>Lipids</source><year>2001</year><volume>36</volume><issue>suppl</issue><fpage>S45</fpage><lpage>S47</lpage><pub-id pub-id-type="pmid">11837992</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.Y</given-names></name><name><surname>Appel</surname><given-names>L.J</given-names></name><name><surname>Croft</surname><given-names>K.D</given-names></name><name><surname>Miller</surname><given-names>E.R. 3rd</given-names></name><name><surname>Mori</surname><given-names>T.A</given-names></name><name><surname>Puddey</surname><given-names>I.B</given-names></name></person-group><article-title>Effects of vitamin C and vitamin E on in vivo lipid peroxidation:
results of a randomized controlled trial</article-title><source>Am J Clin Nutr</source><year>2002</year><volume>76</volume><issue>3</issue><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">12197998</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>M</given-names></name><name><surname>Block</surname><given-names>G</given-names></name><name><surname>Hudes</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antioxidant supplementation decreases lipid peroxidation
biomarker F(2)-isoprostanes in plasma of smokers</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2002</year><volume>11</volume><issue>1</issue><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11815395</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meagher</surname><given-names>E.A</given-names></name><name><surname>Barry</surname><given-names>O.P</given-names></name><name><surname>Lawson</surname><given-names>J.A</given-names></name><name><surname>Rokach</surname><given-names>J</given-names></name><name><surname>FitzGerald</surname><given-names>G.A</given-names></name></person-group><article-title>Effects of vitamin E on lipid peroxidation in healthy persons</article-title><source>JAMA</source><year>2001</year><volume>285</volume><issue>9</issue><fpage>1178</fpage><lpage>1182</lpage><pub-id pub-id-type="pmid">11231747</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davi</surname><given-names>G</given-names></name><name><surname>Ciabattoni</surname><given-names>G</given-names></name><name><surname>Consoli</surname><given-names>A</given-names></name><etal/></person-group><article-title>In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation
in diabetes mellitus: effects of improved metabolic control and vitamin E
supplementation</article-title><source>Circulation</source><year>1999</year><volume>99</volume><issue>2</issue><fpage>224</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">9892587</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Greater oxidative stress in healthy young men compared
with premenopausal women</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><issue>3</issue><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">11884287</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>J.H</given-names></name><name><surname>Kim</surname><given-names>O.Y</given-names></name><name><surname>Park</surname><given-names>H.Y</given-names></name><name><surname>Lee</surname><given-names>S.Y</given-names></name></person-group><article-title>Consumption of whole grain and legume powder reduces insulin demand, lipid
peroxidation, and plasma homocysteine concentrations in patients with coronary artery disease: randomized controlled clinical trial</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2001</year><volume>21</volume><issue>12</issue><fpage>2065</fpage><lpage>2071</lpage><pub-id pub-id-type="pmid">11742886</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>H.J</given-names></name><name><surname>Heimendinger</surname><given-names>J</given-names></name><name><surname>Haegele</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of increased vegetable and fruit consumption on markers
of oxidative cellular damage</article-title><source>Carcinogenesis</source><year>1999</year><volume>20</volume><issue>12</issue><fpage>2261</fpage><lpage>2266</lpage><pub-id pub-id-type="pmid">10590217</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>R</given-names></name><name><surname>van Vliet</surname><given-names>T</given-names></name><name><surname>Broekmans</surname><given-names>W.M</given-names></name><etal/></person-group><article-title>A vegetable/fruit concentrate with high antioxidant capacity
has no effect on biomarkers of antioxidant status in male smokers</article-title><source>J Nutr</source><year>2001</year><volume>131</volume><issue>6</issue><fpage>1714</fpage><lpage>1722</lpage><pub-id pub-id-type="pmid">11385058</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hodgson</surname><given-names>J.M</given-names></name><name><surname>Croft</surname><given-names>K.D</given-names></name><name><surname>Mori</surname><given-names>T.A</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name><name><surname>Beilin</surname><given-names>L.J</given-names></name><name><surname>Puddey</surname><given-names>I.B</given-names></name></person-group><article-title>Regular ingestion of tea does not inhibit in vivo lipid peroxidation in humans</article-title><source>J Nutr</source><year>2002</year><volume>132</volume><issue>1</issue><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">11773508</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abu-Amsha</surname><given-names>Caccetta R</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name><name><surname>Mori</surname><given-names>T.A</given-names></name><name><surname>Beilin</surname><given-names>L.J</given-names></name><name><surname>Puddey</surname><given-names>I.B</given-names></name><name><surname>Croft</surname><given-names>K.D</given-names></name></person-group><article-title>Red wine polyphenols, in the absence of alcohol, reduce lipid peroxidative
stress in smoking subjects</article-title><source>Free Radic Biol Med</source><year>2001</year><volume>30</volume><issue>6</issue><fpage>636</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">11295361</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Moro</surname><given-names>K</given-names></name><name><surname>Nakamori</surname><given-names>K</given-names></name><etal/></person-group><article-title>Increase of antioxidative potential of rat plasma by oral administration
of proanthocyanidin-rich extract from grape seeds</article-title><source>J Agric Food Chem</source><year>1999</year><volume>47</volume><issue>5</issue><fpage>1892</fpage><lpage>1897</lpage><pub-id pub-id-type="pmid">10552467</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conquer</surname><given-names>J.A</given-names></name><name><surname>Maiani</surname><given-names>G</given-names></name><name><surname>Azzini</surname><given-names>E</given-names></name><name><surname>Raguzzini</surname><given-names>A</given-names></name><name><surname>Holub</surname><given-names>B.J</given-names></name></person-group><article-title>Supplementation with quercetin markedly increases plasma quercetin concentration
without effect on selected risk factors for heart disease in healthy subjects</article-title><source>J Nutr</source><year>1998</year><volume>128</volume><issue>3</issue><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">9482769</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gokce</surname><given-names>N</given-names></name><name><surname>Keaney</surname><given-names>J.F.</given-names><suffix>Jr</suffix></name><name><surname>Hunter</surname><given-names>L.M</given-names></name><name><surname>Watkins</surname><given-names>M.T</given-names></name><name><surname>Menzoian</surname><given-names>J.O</given-names></name><name><surname>Vita</surname><given-names>J.A</given-names></name></person-group><article-title>Risk stratification for postoperative cardiovascular events via noninvasive
assessment of endothelial function: a prospective study</article-title><source>Circulation</source><year>2002</year><volume>105</volume><issue>13</issue><fpage>1567</fpage><lpage>1572</lpage><pub-id pub-id-type="pmid">11927524</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furumoto</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name><name><surname>Mikami</surname><given-names>T</given-names></name><name><surname>Kitabatake</surname><given-names>A</given-names></name></person-group><article-title>Relationships between brachial artery flow mediated dilation
and carotid artery intima-media thickness in patients with
suspected coronary artery disease</article-title><source>Jpn Heart J</source><year>2002</year><volume>43</volume><issue>2</issue><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">12025898</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>Tardif</surname><given-names>J.C</given-names></name><name><surname>Cernacek</surname><given-names>P</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name></person-group><article-title>Cholesterol reduction rapidly improves endothelial function
after acute coronary syndromes. The RECIFE (reduction of cholesterol
in ischemia and function of the endothelium) trial</article-title><source>Circulation</source><year>1999</year><volume>99</volume><issue>25</issue><fpage>3227</fpage><lpage>3233</lpage><pub-id pub-id-type="pmid">10385495</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perticone</surname><given-names>F</given-names></name><name><surname>Ceravolo</surname><given-names>R</given-names></name><name><surname>Pujia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognostic significance of endothelial dysfunction in hypertensive patients</article-title><source>Circulation</source><year>2001</year><volume>104</volume><issue>2</issue><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">11447085</pub-id></citation></ref></ref-list></back></article>





